Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients - Trial NCT06421870
Access comprehensive clinical trial information for NCT06421870 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ain Shams University and is currently Recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 210 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ain Shams University
Timeline & Enrollment
Phase 3
Mar 01, 2024
Jul 01, 2025
Primary Outcome
Change in estimated glomerular filtration rate,Change in proteinuria
Summary
Kidneys have a vital role in glucose homeostasis by various mechanisms, one of the major
 mechanisms is through SGLT2. This role was commonly overlooked till development of the new
 SGLT2 inhibitors. (Ni, L., et al 2020) The SGLT2 inhibitor class of glucose-lowering agents
 has recently shown beneficial effects to reduce the onset and progression of renal
 complications in people with and without diabetes, through slow the decline in glomerular
 filtration rate (GFR), delaying the onset of microalbuminuria and slow or reverse the
 progression of proteinuria. (Nespoux, J., & Vallon, V. 2020) The drug pentoxifylline is a
 methyl-xanthine derivative and a nonselective phosphodiesterase inhibitor with
 anti-inflammatory, antiproliferative and antifibrotic actions currently indicated for
 peripheral artery disease. (Panchapakesan U et al.,2018) Chronic kidney disease is a
 progressive disorder in which patients are treated according to complications presented such
 as hypocalcemia, hyperkalemia, anemia and metabolic acidosis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06421870
Non-Device Trial